A retrospective analysis of discontinuation rates and reasons for discontinuation in multiple sclerosis patients treated with delayed-release dimethyl fumarate (Biogen ONE Support Program)

被引：0
|
作者：
Vorobeychik, G. [1 ]
Potts, J. [2 ]
Smith, M. [3 ]
Vlaicu, M. [3 ]
机构：
[1] Fraser Hlth Multiple Sclerosis Clin, Burnaby, BC, Canada
[2] Biogen, Cambridge, MA USA
[3] Biogen, Mississauga, ON, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P638
引用
收藏
页码：301 / 302
页数：2
相关论文
共 50 条
  • [21] Delayed-Release Dimethyl Fumarate Safety and Efficacy in Pediatric Patients With Relapsing-Remitting Multiple Sclerosis
    Alroughani, Raed
    Huppke, Peter
    Mazurkiewicz-Beldzinska, Maria
    Blaschek, Astrid
    Valis, Martin
    Aaen, Gregory
    Pultz, Joe
    Peng, Xiaomei
    Beynon, Vanessa
    FRONTIERS IN NEUROLOGY, 2021, 11
  • [22] PATIENT CHARACTERISTICS AND TREATMENT ADHERENCE AMONG PATIENTS TREATED WITH DELAYED-RELEASE DIMETHYL FUMARATE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN ISRAEL
    Desai, U.
    Huang, M.
    Kirson, N. Y.
    King, S.
    Hellstern, M.
    Schonfeld, S.
    Birnbaum, H. G.
    Lee, A.
    VALUE IN HEALTH, 2017, 20 (05) : A195 - A195
  • [23] Efficacy of delayed-release dimethyl fumarate in multiple sclerosis patients with moderate disability: an integrated analysis of the phase 3 studies
    Hutchinson, M.
    Zhang, A.
    Yang, M.
    Okwuokenye, M.
    Kurukulasuriya, N. C.
    Fox, R. J.
    Gold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 116 - 116
  • [24] Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod
    Hersh, Carrie M.
    Harris, Haleigh
    Ayers, Malissa
    Conway, Devon
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2020, 6 (04)
  • [25] Absolute Lymphocyte Count in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: Considerations for Patient Management
    Fox, Robert
    Chan, Andrew
    Gold, Ralf
    Phillips, J. Theodore
    Yang, Lili
    Liu, Shifang
    Prada, Claudia
    Ray, Soma
    Mehta, Devangi
    Taylor, Catherine
    Fay, Monica
    NEUROLOGY, 2017, 88
  • [26] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL FUMARATE FOR THE TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Gasche, D.
    Restovic, G.
    Casado, V
    Ramirez-Boix, P.
    Martinez Lopez, J.
    VALUE IN HEALTH, 2015, 18 (07) : A755 - A755
  • [27] Delayed-release dimethyl fumarate and disability assessed by the multiple sclerosis functional composite: integrated analysis of DEFINE and CONFIRM
    Giovannoni, G.
    Gold, R.
    Kappos, L.
    Arnold, D. L.
    Bar-Or, A.
    Kurukulasuriya, N. C.
    Yang, M.
    Sarda, S. P.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 92 - 92
  • [28] Effect of aspirin on flushing in relapsing-remitting multiple sclerosis patients receiving delayed-release dimethyl fumarate
    Rog, D.
    Cader, S.
    Harrower, T.
    McGuigan, C.
    Young, C.
    Potts, J.
    Hanna, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 656 - 657
  • [29] Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate
    Lori Mayer
    Mary Kay Fink
    Carrie Sammarco
    Lisa Laing
    Drug Safety, 2018, 41 : 347 - 356
  • [30] Pregnancy Outcomes From an International Registry of Patients Treated With Delayed-release Dimethyl Fumarate
    Everage, Nicholas J.
    Jones, Cynthia C.
    Hellwig, Kerstin
    Rog, David
    Liu, Shifang
    Mou, Jiani
    Prada, Claudia
    Hanna, Jerome
    NEUROLOGY, 2019, 92 (15)
12345